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Immunomodulation by mesenchymal stem cells 
in vitro and in vivo
Mesenchymal stem cells (MSCs) are multipotent 
progenitor cells that can be cultured from various adult 
and fetal tissues and that are capable of diﬀ  erentiating 
into multiple mesenchymal lineages including bone, 
cartilage, tendon, marrow stroma and adipose tissue [1]. 
Because of their unique regenerative potential, MSCs are 
considered a promising therapeutic modality for tissue 
regeneration and repair. Moreover, MSCs are thought to 
be critically involved in the formation of survival niches 
for memory T cells and B cells in the bone marrow, 
thereby regulating the size, stability and plasticity of 
immunological memory.
Awareness has additionally been raised by the ﬁ  nding 
that MSCs display immunomodulatory properties in 
vitro, as evidenced by their ability to inhibit T-cell proli-
fera tion.  Th  is  inhibition aﬀ  ects the proliferation of T cells 
induced by alloantigens,  mitogens and CD3-ligation. 
More  over, MSCs have also been shown to inhibit the 
proliferation of B cells, and possibly the activity of natural 
killer cells. Th  e molecular interactions responsible for 
these inhibitory eﬀ  ects observed in vitro are the subject 
of intense investigations and include the action of prosta-
glandin E2, nitric oxide, indoleamine 2,3-dioxygenase and 
programmed death ligand-1 [2].
Because of their potent inhibitory eﬀ  ects  in vitro, 
MSCs have been used in several preclinical disease 
models, most often aiming to inhibit alloreactive immunity 
such as is observed in graft-versus-host disease (GVHD), 
and in transplantation models. Several studies have now 
shown that  infusions of MSCs can be eﬀ  ective  in 
controlling GVHD or in promoting engraftment and 
survival of allogeneic bone marrow cells. Opposing 
obser  vations have also been reported, however, as injec-
tion of allogeneic MSCs has been shown to trigger allo-
speciﬁ   c immune responses in vivo resulting  in graft 
rejection [3]. Th   erefore it is conceivable that the modula-
tory eﬀ  ects observed in in vivo transplantation models 
are not all mediated by immune suppression, but possibly 
also through other mechanisms. Th   e latter are presently 
not known, but could include production of MSC-
derived cytokines capable of expanding alloreactive 
natural killer cells. Such natural killer cells can eﬃ   ciently 
kill donor/host-derived professional antigen-presenting 
cells and thereby inhibit the induction of allo-speciﬁ  c 
T-cell responses [4,5].
Th   e observation that MSCs themselves can induce allo-
reactive T-cell responses indicates a discrepancy between 
in vivo ﬁ   ndings and the immunosuppressive in vitro
ﬁ  ndings as also observed by Schurgers and colleagues. 
Although this is poorly understood, MSC-based inter-
ventions are already pioneered in the clinical setting and 
the ﬁ   rst promising results have been reported in the 
context of human GVHD [6] and Crohn’s disease [7].
Mesenchymal stem cells in autoimmune rheumatic 
diseases
Despite these promising results from transplantation 
settings, eﬀ  ects in preclinical autoimmune disease models 
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© 2010 BioMed Central Ltdare less coherent. Some studies report amelioration of 
arthritic symptoms in preclinical arthritis models, 
whereas other studies – such as that by Schurgers and 
colleagues – could not report beneﬁ  cial eﬀ  ects or even 
describe a worsening of the disease course [1,8]. Th  e 
latter could in part be related to the use of allogeneic 
MSCs, as it has been reported that the use of allogeneic 
cells – presumably through additional cytokine release as 
a consequence of the underlying allo response – leads to 
the exacerbation of arthritis [9]. Furthermore, direct 
comparison of these studies is hampered by the use of 
diﬀ   erent MSC culture conditions in vitro, diﬀ  erent 
tissues from which the MSCs are derived, and a variety of 
diﬀ  erent administration schedules currently used in vivo. 
Moreover, studies on the phenotype of MSCs in bone 
marrow indicate that MSCs are a heterogeneous popu-
lation comprised of subpopulations that diﬀ  eren  tially 
express a number of receptors to interact with immune-
competent eﬀ  ector cells. Th   e ability of MSCs to modulate 
immune responses therefore probably depends, in part, 
on the composition of the starting population.
Despite our incomplete understanding of the mecha-
nisms underlying these divergent results, and inspired by 
positive reports on the use of bone marrow-derived 
MSCs in the outcome of GVHD and transplantation 
engraft  ment without the observation of severe side 
eﬀ   ects associated with the infusion of MSC, the ﬁ  rst 
studies in human autoimmune disease are already 
appear  ing [10,11]. Not unexpectedly, however, the 
clinical eﬀ  ects are not coherent.
Concluding remarks
Th   e mechanisms underlying the possible in vivo 
immuno modulatory eﬀ  ects of MSCs remain a critical and 
unresolved question. By comparing side by side the 
eﬀ  ects  of  MSCs  in vitro and in vivo, the study by 
Schurgers and colleagues brings fresh encouragement to 
the endeavors to elucidate the immunomodulatory 
eﬀ   ects of MSCs in rheumatic diseases [1]. Given the 
apparent diﬃ   culties in recapitulating the in vitro eﬀ  ects 
in vivo,  however, researchers should be cautioned and 
should remain critical concerning the use of MSCs for 
the treatment of human autoimmune disease. It is likely 
that the endeavors will eventually pay oﬀ   , but more 
experience with the use of MSCs in the setting of GVHD 
can help guide their use for rheumatic diseases, thereby 
certifying or revoking their therapeutic use for the 
control of autoimmunity.
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